# Lung Stereotactic Body Radiation Therapy in a Patient with Severe Lung Function Impairment Allowed by Gallium-68 Perfusion PET/CT Imaging: A Case Report

François Lucia, Mohamed Hamya, Fanny Pinot, David Bourhis, Pierre-Yves

Le Roux

► To cite this version:

François Lucia, Mohamed Hamya, Fanny Pinot, David Bourhis, Pierre-Yves Le Roux. Lung Stereotactic Body Radiation Therapy in a Patient with Severe Lung Function Impairment Allowed by Gallium-68 Perfusion PET/CT Imaging: A Case Report. Diagnostics, 2023, 13 (4), pp.718. 10.3390/diagnostics13040718. [https://doi.org/10.3390/diagnostics13040718](https://doi.org/10.3390/diagnostics13040718)

HAL Id: hal-05249294

https://hal.univ-brest.fr/hal-05249294v1

Submitted on 11 Sep 2025

HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d'enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.

<figure><img src="image_1.png" /></figure>

Distributed under a Creative Commons Attribution 4.0 International License
Interesting Images

# Lung Stereotactic Body Radiation Therapy in a Patient with Severe Lung Function Impairment Allowed by Gallium-68 Perfusion PET/CT Imaging: A Case Report

François Lucia<sup>1,2,*</sup> <sup>1</sup>, Mohamed Hamya<sup>1</sup>, Fanny Pinot<sup>3</sup>, David Bourhis<sup>3</sup> and Pierre-Yves Le Roux<sup>3,5</sup>

**Abstract:** Lung stereotactic body radiotherapy (SBRT) is increasingly proposed, especially for patients with poor lung function who are not eligible for surgery. However, radiation-induced lung injury remains a significant treatment-related adverse event in these patients. Moreover, for patients with very severe COPD, we have very few data about the safety of SBRT for lung cancer. We present the case of a female with very severe chronic obstructive pulmonary disease (COPD) with a forced expiratory volume in one second (FEV1) of 0.23 L (11%), for whom a localized lung tumor was found. Lung SBRT was the only possible treatment. It was allowed and safely performed, based on a pre-therapeutic evaluation of regional lung function with Gallium-68 perfusion lung positron emission tomography combined with computed tomography (PET/CT). This is the first case report to highlight the potential use of a Gallium-68 perfusion PET/CT in order to safely select patients with very severe COPD who can benefit from SBRT.

**Keywords:** Gallium-68 perfusion lung PET/CT; stereotactic radiotherapy; radiation-induced lung injury; very severe chronic obstructive pulmonary disease; case report

<figure><img src="image_2.png" /></figure>

check for
updates

**Citation:** Lucia, F.; Hamya, M.; Pinot, F.; Bourhis, D.; Le Roux, P.-Y. Lung Stereotactic Body Radiation Therapy in a Patient with Severe Lung Function Impairment Allowed by Gallium-68 Perfusion PET/CT
**Imaging:** A Case Report. *Diagnostics* **2023**, *13*, 718. https://doi.org/10.3390/diagnostics13040718

Academic Editor: Andor
W.J.M. Glaudemans

Received: 1 February 2023

Revised: 9 February 2023

Accepted: 13 February 2023

Published: 14 February 2023

<figure><img src="image_3.png" /></figure>

**Copyright:** © 2023 by the authors.
Licensee MDPI, Basel, Switzerland.
This article is an open access article
distributed under the terms and
conditions of the Creative Commons
Attribution (CC BY) license (https://
creativecommons.org/licenses/by/
4.0/).

<footnote n="1">¹ Radiation Oncology Department, University Hospital, 29200 Brest, France</footnote>

<footnote n="2">² LaTIM, INSERM, UMR 1101, University of Brest, 29200 Brest, France</footnote>

<footnote n="3">³ Inserm, CHRU Brest, UMR 1304, GETBO, Nuclear Medicine Department, University of Brest, 29238 Brest, France</footnote>

<footnote>* Correspondence: francois.lucia@gmail.com</footnote>
<figure><img src="image_4.png" /></figure>

**Figure 1.** A 73-year-old female had a very severe chronic obstructive pulmonary disease (COPD) with a forced expiratory volume in one second (FEV1) of 0.23 L (11%). The patient received nocturn noninvasive ventilation and permanent oxygenotherapy. She was diagnosed with a lung tumor of the right hilum on chest radiography. On CT, a para-hilar mass of the posterior segment of the right upper lobe was measured to 29 mm × 23 mm in the axial plane (A). This mass was highly hypermetabolic on 18F-FDG PET/CT (B). The lesion was highly suspicious for a primary lung cancer. However, a biopsy was judged to be too risky. Multidisciplinary team meetings were proposed as the only possible therapeutic approach to treat this lesion by stereotactic body radiation therapy (SBRT) without histologic confirmation. Lung SBRT is considered to be a viable treatment option even in patients with poor lung function [1]. However, the reported incidence of symptomatic radiation-induced lung injury (grade ≥ 2) in the published data ranges from 9% to 28% [2–5] and is the most frequent adverse event after lung SBRT. Moreover, for patients with very severe COPD, we have very few data about the safety of SBRT for lung cancer [6,7]. Indeed, most clinical trials of SBRT for lung cancer have only included patients with FEV1 > 0.7 L [6,7]. Furthermore, retrospective studies about outcomes after SBRT in patients with severe COPD had very few patients with FEV1 < 0.7 L [8,9]. Therefore, for a patient with a FEV1 of 0.23 (11%), the therapeutic index was unknown. We decided to evaluate the possibility of treating this tumor with a SBRT protocol of 60 Gy in eight fractions due to the ultra-central localization [10]. This patient benefited from a perfusion PET/CT after the administration of ⁶⁸Gallium-MAA to precisely evaluate lung function distribution and to assess the potential consequences of radiation therapy on lung function (Figure 2). Lung perfusion PET/CT images showed that a large part of the right lung was non-functional, especially the areas around the lung lesion. Lung functional volumes were delineated using a visually adapted semi-automatic method [11], and were co-registered with radiation plans. When we use this SBRT protocol, the dose constraints to both lungs are the anatomical lung volume receiving at least 26 Gy (V26 Gy) < 10% and the mean dose (Dmean) < 7 Gy [10]. However, these dose constraints have been evaluated in patients with FEV1 > 0.7 L and should be lower in patients with FEV1 < 0.7 L. In our case, the V26Gy (yellow line) to the anatomic lung volume was 4.7% versus only 1.1% to the functional lung volume. Furthermore, the Dmean to the anatomical lung volume was 5.29 Gy versus only 2.68 Gy to the functional lung volume. Based on this functional evaluation with functional lung volumes irradiated significantly below the limit values and in the absence of a therapeutic alternative, we approved the
SBRT treatment. At 3 months of treatment, the CT scan showed a partial response to radiotherapy 15 vs. 29 mm (−49%) according to the Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) (Figure 3) [12]. Toxicity was assessed using the Common Terminology Criteria for Adverse Events, version 5.0, with three questionnaires about quality of life (QLQ-C30, QLQ-LC13, and EQ-5D-5L) and with pulmonary function test. The patient experienced no side effects, and spirometry showed a FEV1 of 0.27 L (13%). Lung SBRT is the standard of care to treat inoperable stage 1 and 2 lung cancer [1]. However, the reported incidence of symptomatic radiation-induced lung injury (grade ≥ 2) in the published data ranges from 9% to 28% [1] and is the most frequent adverse event after lung SBRT. Moreover, most retrospective studies and ongoing clinical trials of SBRT for lung cancer have only included patients with a forced expiratory volume in one second (FEV1) > 0.7 L [6,8]. Therefore, for a patient with a FEV1 < 0.7 L, the therapeutic index is unknown. Patients with severe COPD frequently demonstrate high heterogeneity of regional lung function, with non-functional areas alternating with still functional regions, which should be preserved as much as possible. Lung perfusion PET/CT imaging is a novel imaging technique for regional lung function evaluation. Similar to conventional lung perfusion scintigraphy, images are obtained after intravenous administration of macro-aggregated albumin (MAA) particles, which embolize in the pulmonary capillaries according to pulmonary blood flow. However, as compared with lung scintigraphy, these molecules are not radiolabeled with Technetium-99m, but with Gallium-68, a β+ isotope, allowing image acquisition with PET technology [13]. PET is an intrinsically superior technique for image acquisition, with greater sensitivity and better spatial and temporal resolutions [14,15]. This offers the opportunity to improve the accuracy of lung functional volumes delineation and its integration in thoracic radiation therapy planning. Indeed, unlike surgery, radiation therapy requires a more accurate assessment of the distribution of lung function because radiation doses can be given to both lungs, not just the tumor-affected lobe. Siva et al. demonstrated the feasibility of preserving lung functional volumes in a cohort of 14 patients treated with 3D conformal radiotherapy for NSCLC adapted to ⁶⁸Ga-perfusion PET/CT [16]. However, SBRT is a more precise and conformal technique that allows the irradiation of smaller volumes of organs at risk (OARs) [17]. To date, no study has evaluated the performance of ⁶⁸Ga-perfusion PET/CT imaging to personalize lung SBRT planning and dosimetry. In our case, the performance of lung perfusion PET/CT allowed a more accurate assessment of the doses delivered to the functional lung volume at the time of radiotherapy planning than lung perfusion scintigraphy. These data allowed us to improve the prediction of the risk of toxicity in this patient and to evaluate it as very low. This case report illustrates the potential use of a Gallium-68 perfusion PET/CT in order to safely select patients with very severe COPD who can benefit from SBRT.

<figure><img src="image_5.png" /><figcaption>**Figure 2.** Axial (**left**), coronal (**middle**), and sagittal (**right**) slices of registration between lung perfusion PET/CT using Gallium-68-MAA (in red: the most functional areas; in blue: the least functional areas) and treatment planning computed tomography simulation scan. The planning target volume (PTV) is contoured in red; the V26Gy is the yellow line.</figcaption></figure>
<figure><img src="image_6.png" /><figcaption>**Figure 3.** Computed tomography scan at 5 months of lung stereotactic radiotherapy.</figcaption></figure>

**Author Contributions:** Conceptualization: F.L. and P.-Y.L.R.; methodology: F.L. and P.-Y.L.R.; software: D.B.; investigation: F.L., P.-Y.L.R., M.H. and F.P.; data curation: F.L., M.H. and F.P.; writing—original draft preparation: F.L., M.H. and P.-Y.L.R.; writing—review and editing: F.L., M.H., F.P. and P.-Y.L.R.; supervision: P.-Y.L.R.; project administration: F.L. and P.-Y.L.R. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research received no external funding.

**Institutional Review Board Statement:** The study was approved by the Nord Ouest IV Ethics Committee (ID RCB: 2021-002224-20) and registered in ClinicalTrial.gov registry (NCT04942275).

**Informed Consent Statement:** Informed consent was obtained from all subjects involved in the study.

**Data Availability Statement:** Research data are stored in an institutional repository and will be shared upon request to the corresponding author.

**Conflicts of Interest:** The authors declare no conflict of interest.

## References

1. Saha, A.; Beasley, M.; Hatton, N.; Dickinson, P.; Franks, K.; Clarke, K.; Jain, P.; Teo, M.; Murray, P.; Lilley, J. Clinical and dosimetric predictors of radiation pneumonitis in early-stage lung cancer treated with Stereotactic Ablative radiotherapy (SABR)—An analysis of UK's largest cohort of lung SABR patients. *Radiother. Oncol.* **2021**, *156*, 153–159. [CrossRef] [PubMed]

2. Barriger, R.B.; Forquer, J.A.; Brabham, J.G.; Andolino, D.L.; Shapiro, R.H.; Henderson, M.A.; Johnstone, P.A.; Fakiris, A.J. A dose-volume analysis of radiation pneumonitis in non-small cell lung cancer patients treated with stereotactic body radiation therapy. *Int. J. Radiat. Oncol. Biol. Phys.* **2012**, *82*, 457–462. [CrossRef] [PubMed]

3. Bongers, E.M.; Botticella, A.; Palma, D.A.; Haasbeek, C.J.; Warner, A.; Verbakel, W.F.; Slotman, B.; Ricardi, U.; Senan, S. Predictive parameters of symptomatic radiation pneumonitis following stereotactic or hypofractionated radiotherapy delivered using volumetric modulated arcs. *Radiother. Oncol.* **2013**, *109*, 95–99. [CrossRef] [PubMed]

4. Matsuo, Y.; Shibuya, K.; Nakamura, M.; Narabayashi, M.; Sakanaka, K.; Ueki, N.; Miyagi, K.; Norihisa, Y.; Mizowaki, T.; Nagata, Y.; et al. Dose-volume metrics associated with radiation pneumonitis after stereotactic body radiation therapy for lung cancer. *Int. J. Radiat. Oncol. Biol. Phys.* **2012**, *83*, e545–e549. [CrossRef] [PubMed]

5. Nakamura, M.; Nishimura, H.; Nakayama, M.; Mayahara, H.; Uezono, H.; Harada, A.; Hashimoto, N.; Ejima, Y.; Ishihara, T.; Sasaki, R. Dosimetric factors predicting radiation pneumonitis after CyberKnife stereotactic body radiotherapy for peripheral lung cancer. *Br. J. Radiol.* **2016**, *89*, 20160560. [CrossRef] [PubMed]
6. Kimura, T.; Nagata, Y.; Eba, J.; Ozawa, S.; Ishikura, S.; Shibata, T.; Ito, Y.; Hiraoka, M.; Nishimura, Y. Radiation Oncology Study Group of the Japan Clinical Oncology G: A randomized Phase III trial of comparing two dose-fractionations stereotactic body radiotherapy (SBRT) for medically inoperable Stage IA non-small cell lung cancer or small lung lesions clinically diagnosed as primary lung cancer: Japan Clinical Oncology Group Study JCOG1408 (J-SBRT trial). *Jpn. J. Clin. Oncol.* **2017**, *47*, 277-281. [PubMed]

7. Nagata, Y.; Hiraoka, M.; Shibata, T.; Onishi, H.; Kokubo, M.; Karasawa, K.; Shioyama, Y.; Onimaru, R.; Kozuka, T.; Kunieda, E.; et al. Prospective Trial of Stereotactic Body Radiation Therapy for Both Operable and Inoperable T1N0M0 Non-Small Cell Lung Cancer: Japan Clinical Oncology Group Study JCOG0403. *Int. J. Radiat. Oncol. Biol. Phys.* **2015**, *93*, 989-996. [CrossRef] [PubMed]

8. Palma, D.; Lagerwaard, F.; Rodrigues, G.; Haasbeek, C.; Senan, S. Curative treatment of Stage I non-small-cell lung cancer in patients with severe COPD: Stereotactic radiotherapy outcomes and systematic review. *Int. J. Radiat. Oncol. Biol. Phys.* **2012**, *82*, 1149-1156. [CrossRef] [PubMed]

9. Abe, T.; Ryuno, Y.; Saito, S.; Aoshika, T.; Igari, M.; Hirai, R.; Kumazaki, Y.; Kaira, K.; Kagamu, H.; Ishida, H.; et al. Stereotactic body radiation therapy using CyberKnife for T1N0M0 lung cancer patients with severe pulmonary dysfunction. *J. Radiat. Res.* **2020**, *61*, 903-907. [CrossRef] [PubMed]

10. Zhao, Y.; Khawandanh, E.; Thomas, S.; Zhang, S.; Dunne, E.M.; Liu, M.; Schellenberg, D. Outcomes of stereotactic body radiotherapy 60 Gy in 8 fractions when prioritizing organs at risk for central and ultracentral lung tumors. *Radiat. Oncol.* **2020**, *15*, 61. [CrossRef] [PubMed]

11. Le Roux, P.Y.; Siva, S.; Callahan, J.; Claudic, Y.; Bourhis, D.; Steinfort, D.P.; Hicks, R.J.; Hofman, M.S. Automatic delineation of functional lung volumes with ⁶⁸Ga-ventilation/perfusion PET/CT. *EJNMMI Res.* **2017**, *7*, 82. [CrossRef] [PubMed]

12. Schwartz, L.H.; Litiere, S.; de Vries, E.; Ford, R.; Gwyther, S.; Mandrekar, S.; Shankar, L.; Bogaerts, J.; Chen, A.; Dancey, J.; et al. RECIST 1.1-Update and clarification: From the RECIST committee. *Eur. J. Cancer* **2016**, *62*, 132-137. [CrossRef] [PubMed]

13. Blanc-Beguin, F.; Hennebicq, S.; Robin, P.; Tripier, R.; Salaun, P.Y.; Le Roux, P.Y. Radiopharmaceutical Labelling for Lung Ventilation/Perfusion PET/CT Imaging: A Review of Production and Optimization Processes for Clinical Use. *Pharmaceuticals* **2022**, *15*, 518. [CrossRef] [PubMed]

14. Le Roux, P.Y.; Hicks, R.J.; Siva, S.; Hofman, M.S. PET/CT Lung Ventilation and Perfusion Scanning using Galligas and Gallium-68-MAA. *Semin. Nucl. Med.* **2019**, *49*, 71-81. [CrossRef] [PubMed]

15. Hicks, R.J.; Hofman, M.S. Is there still a role for SPECT-CT in oncology in the PET-CT era? *Nat. Rev. Clin. Oncol.* **2012**, *9*, 712-720. [CrossRef] [PubMed]

16. Siva, S.; Devereux, T.; Ball, D.L.; MacManus, M.P.; Hardcastle, N.; Kron, T.; Bressel, M.; Foroudi, F.; Plumridge, N.; Steinfort, D.; et al. Ga-68 MAA Perfusion 4D-PET/CT Scanning Allows for Functional Lung Avoidance Using Conformal Radiation Therapy Planning. *Technol. Cancer Res. Treat.* **2016**, *15*, 114-121. [CrossRef] [PubMed]

17. Ball, D.; Mai, G.T.; Vinod, S.; Babington, S.; Ruben, J.; Kron, T.; Chesson, B.; Herschtal, A.; Vanevski, M.; Rezo, A.; et al. Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): A phase 3, open-label, randomised controlled trial. *Lancet Oncol.* **2019**, *20*, 494-503. [CrossRef] [PubMed]

**Disclaimer/Publisher's Note:** The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.